Fredrik Wiklund serves as our President and Chief Executive Officer, having previously served as our Chief Operating Officer since January 2020. Fred brings over 20 years of operational experience with significant breadth of management responsibility with both emerging and large biotechnology companies. Most recently, Fred served as the Chief Operating Officer at Bioniz Therapeutics Inc., a company developing cytokine-based therapies for the treatment of cancer and autoimmune diseases. At Bioniz, Fred negotiated the company’s ~$500M Option and Merger agreement with Almirall S.A. in late 2019. Previously, Fred served as the Vice President of Corporate Development and later as President and Chief Executive Officer of Celladon Corporation (CLDN). Under Fred’s leadership, Celladon completed an IPO in 2014 and merged with Eiger Pharmaceuticals in 2016. Before Celladon, Fred served as Head of Corporate Development and Investor Relations at Tercica Inc. (TRCA) where he guided the company through its IPO and later its ~$650M acquisition by the Ipsen Group in 2009. Earlier, Fred was an investment banker with Lehman Brothers serving in the Healthcare Group based in London, UK. Fred also spent five years at Gilead Sciences where he helped launch Gilead’s first commercial product in 1996. Fred holds a Bachelor of Arts from University of San Diego and a Master of Business Administration from the University of Southern California.